Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-03-01
2011-03-01
Robinson, Hope A (Department: 1652)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600
Reexamination Certificate
active
07897567
ABSTRACT:
Damage to cells and/or a subject caused by radiation is treated or prevented by administration of an alpha thymosin peptide.
REFERENCES:
patent: 4079127 (1978-03-01), Goldstein et al.
patent: 4179337 (1979-12-01), Davis et al.
patent: 4353821 (1982-10-01), Birr et al.
patent: 5585352 (1996-12-01), Goldstein et al.
patent: 6197751 (2001-03-01), Malinda et al.
patent: 6309633 (2001-10-01), Ekwuribe et al.
patent: 2005/0049191 (2005-03-01), Ruldolph et al.
patent: 1303713 (2001-07-01), None
patent: 1195980 (1970-06-01), None
patent: 94/13314 (1994-06-01), None
patent: 0182949 (2001-11-01), None
patent: 0236169 (2002-05-01), None
patent: WO 03/037272 (2003-05-01), None
Auger et al. The Journal of Histochemistry and Cytochemistry, vol. 35, No. 2, pp. 181-187, 1987.
Caldarella et al. (PNAS, vol. 80, Dec. 1983, pp. 7424-7427).
Belyakov et al., “Serum Alpha-1-Thymosin Level and T-Lymphocyte Population Composition in Irradiated Subjects at Late Periods After Radiation Accident,” Immunologiya, No. 2, 1992, pp. 30-33.
Gray et al., “Thymosin Alpha1 (Ta-1) Modulation of Irradiation-Induces Cellular Immune Deficiency,” Proceedings of the American Association for Cancer Research, vol. 26, Mar. 1985, p. 1106, XP009095398.
Ishitsuka et al., “Efficacy of Thymosin Alpha1 in Animal Models” Thymic Hormones and Lymphokines: Basic Chemical and Clinical Applications, 1984, pp. 925-438.
Schulof et al., “Synthetic Thymosin Alpha1 Following Mediastinal Irradiation: A Randomized Trial in Patients With Locally Advanced Non-Small Cell Lung Cancer,” Proceedings of the American Society of Clinical Oncology (Asco Abstracts, Clinical Trials: Lung), vol. 2, Mar. 1983, p. 185, XP009104106.
Shmelev et al., “Thymosin Alpha-1 and Hybrid Proteins Consisting of Tumor Necrosis Factor-Alpha and Thymosin Alpha-1 Enchance the Efficacy of Vaccination Against the Causative Agent of Plague.” Zhurnal Mikrobiologii, Epidemiologii, I Immunobiologii, No. 4, Jul. 1994-Aug. 1994, pp. 85-89.
Doria, et al., “Radiation Damage and Recovery of the Immune System” Eur Report, Commission of the European Communities, 1984, EUR-9088, p. 524-527.
Ishitsuka, H. et al., “Efficacy of Thymosin alpha 1in animal models” Thymic hormones and lymphokines: basic chemistry and clinical applications, xx, xx, 1984, pp. 425-438.
JP Application 555637/2004 Office Action mailed Jan. 5, 2010.
NO Application 20052943 mailed Oct. 27, 2009 with English translation.
PO Application P 377376 Office Action dated Mar. 10, 2010.
Vavrova, J., et al., “The Effect of Thymic Humoral Factor upon Regeneration of Lymphatic and Haemopoietic Tissues of Irradiated Mice” 1975, Folia Biologica, 21(4) 238-243.
Vavrova, J., et al., “The Effect of Thymosin Application upon Radiation Sickness in Mice” 1976, Folia Biologica, 22 (5), 320-329.
Rudolph Alfred R.
Tuthill Cynthia W.
Cooley LLP
Robinson Hope A
SciClone Pharmaceuticals Inc.
LandOfFree
Methods of protecting against radiation damage using alpha... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of protecting against radiation damage using alpha..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of protecting against radiation damage using alpha... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2744111